We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
PETER
HOSKIN
peterhoskin@nhs.net
Lucy
Collins
lucy.collins8@nhs.net
Prof
PETER
HOSKIN
peterhoskin@nhs.net
Louise
Peacock
louise.peacock6@nhs.net
Diseases of male genital organsMalignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
One of the common treatments for early prostate cancer is brachytherapy. This delivers radiation directly into the prostate gland by placing radioactive sources within the gland. It is therefore entirely feasible to treat only part of the gland by placing sources in only the region to be targeted.
A common and distressing side effect of any treatment for prostate cancer is erectile dysfunction. It is proposed that treating only part of the prostate gland may help men keep their sexual function by avoiding the regions important for achieving erection. This study will try to answer this question. We will invite men with early prostate cancer, confined to one half of the prostate and suitable for brachytherapy, to be assigned to one of two groups. The first group will receive usual brachytherapy to the whole prostate gland. The second group will receive treatment only to the half of the prostate that contains cancer. We will then find out whether fewer patients in the group with only part of the prostate gland treated have less erectile dysfunction. In addition we will assess long term bladder and bowel side effects which may also be reduced. Participation in the study will last for 5 years. With three years accrual, the study will take 8 years and will involve a total of 254 men across 17 countries.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Radiotherapy;
You can take part if:
You may not be able to take part if:
1. Contraindication for MRI scanning 2. Bleeding disorder preventing invasive treatment as a prostate implantation 3. Not able to stop anti-coagulants 4. Active urinary tract infection 5. Any history of bladder neck stricture 6. Comorbidity preventing general or spinal anesthesia 7. Any history of inflammatory bowel disease 8. Prior or concurrent malignancy except for non-melanoma skin cancer or other malignancy from which the patient has been cured for at least 5 years 9. Life expectancy of < 5 years 10. Prostate calcifications greater than 5 mm 11. Chemotherapy for prostate cancer 12. Hormonal therapy for prostate cancer within 1 year prior to procedure 13. Previous radiation to pelvis 14. Recurrent prostate cancer 15. Transurethral resection of the prostate or urethral stent 16. Prior major rectal surgery (except haemorrhoids) 17. Participation in another clinical trial
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
PETER
HOSKIN
peterhoskin@nhs.net
Lucy
Collins
lucy.collins8@nhs.net
Prof
PETER
HOSKIN
peterhoskin@nhs.net
Louise
Peacock
louise.peacock6@nhs.net
The study is sponsored by Academic Medical Center at the University of Amsterdam (Netherlands) and funded by Stichting Koningin Wilhelmina Fonds voor de Nederlandse Kankerbestrijding .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 48059
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
